老年肺血栓栓塞患者抗凝治疗方案的病例分析  

Case report of anticoagulation methods in an elderly patient with pulmonary embolism

作　　者：杨珍珍 莫合塔伯尔·莫敏 蒋捷[2] 王梓凝[1] YANG Zhen-zhen;MOHERABOER·Mo-min;JIANG Jie;WANG Zi-ning(Department of Pharmacy,Peking University First Hospital,Bejing 100034,China;Departmenot fCardiology,Peking University First Hospital,Bejing 100034,China;Department of Pharmacy,The Second Hospital of Hebei Medical University,Shijiazhuang 050000,Hebei Province,China)

机构地区：[1]北京大学第一医院,药学部,北京100034 [2]北京大学第一医院,心内科,北京100034 [3]河北医科大学第二医院药学部,河北石家庄050000

出　　处：《中国临床药理学杂志》2023年第12期1792-1794,共3页The Chinese Journal of Clinical Pharmacology

基　　金：国家科技重大专项-重大新药创制基金资助项目(2018ZX09201013-003);河北省卫生健康委科研基金资助项目(20230529)。

摘　　要：本文通过分析1例高龄肺血栓栓塞患者口服利伐沙班的治疗过程,探索利伐沙班在该患者中抗Xa因子活性浓度偏高的原因,讨论该患者的最佳抗凝治疗策略,提示临床药师需关注利伐沙班用于高龄患者治疗时药物体内蓄积的可能,并掌握抗Xa因子活性检测及其他相关凝血指标的临床意义。为临床用药提供更多的剂量调整依据。This article analyzed the treatment process of one elderly patient who took rivaroxaban orally for pulmonary thromboembolism,explored the reason why the concentration of anti Xa factor activity of rivaroxaban in this patient was high,discussed the optimal anticoagulant treatment strategy for this patient.All suggested that clinical pharmacists should pay attention to the possibility of rivaroxaban accumulates in elderly patients,and master the clinical significance of anti-factor Xa activity test and other related coagulation parameters in these patients.This review provides more evidences for dose adjustment in clinical medication especially in elder population.

关 键 词：利伐沙班 肺血栓栓塞 抗Xa因子活性 

分 类 号：R69[医药卫生—泌尿科学]